Abstract
Aim: Epoxide hydrolase is involved in oxidative defenses and isresponsible for the activation of carcinogens. The relationship between EPHX1 polymorphisms (Tyr113His and His139Arg)and overall survival (OS) and lung cancer (LC) riskwas investigated. Methods: The study comprised 550 cases and 550 controls. Genotyping and statistical analysis were applied. Results: The variant genotypes of EPHX1 polymorphisms exhibited no association with LC risk. The Tyr113His polymorphism exhibited twofold increased odds of lymph node invasion (p=0.04). The Tyr/His genotype is a risk factor for smokers. Subjects carrying thecombined genotype for His139Arg showed better median survival time(MST)and theheterozygous genotype revealed better MST in the case of small-cell lung cancer(SCLC; 11.30 vs 6.73months;log-rank test: p=0.02). The heterozygous genotype (His139Arg) had longer MST in patients receiving cisplatin/carboplatin and irinotecan (11.30 vs 7.23;log-rank test: p=0.007) Conclusion: The Tyr113His polymorphism is associated with LC risk in smokers and is a potential prognostic factor for OS inpatients withSCLCafter irinotecan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
